Echocardiographic assessment of doxazosin on left ventricular mass in patients with essential hypertension.

Abstract

A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension. The systolic shortening coefficient was also increased and a trend in the improvement of ejection fraction, rate of circumferential fiber shortening, systolic contraction time, and preejective/ejective ratio was observed. No change in heart rate was recorded and no patients had side effects. The serum lipid profile was modified favorably, particularly with regard to the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio. By producing a reduction in blood pressure and left ventricular mass while favorably modifying the serum lipid profile, doxazosin produced a beneficial change in the overall coronary heart disease risk profile.

• Authors: P Monsalve, O Vera, F Pérez Acuña, O Medina, K Ostojich, B López, N Torres, V Lugo de Franco, R Fonseca
• Journal: American heart journal (Am Heart J) Vol. 121 Issue 1 Pt 2 Pg. 356-61 (Jan 1991) ISSN: 0002-8703 [Print] United States
• PMID: 1824661 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antihypertensive Agents
• Lipids
• Cholesterol
• Doxazosin
• Prazosin

Topics

• Antihypertensive Agents (therapeutic use)
• Cardiomegaly (diagnostic imaging, drug therapy)
• Cholesterol (blood)
• Coronary Disease (epidemiology)
• Doxazosin
• Echocardiography
• Female
• Humans
• Hypertension (drug therapy)
• Lipids (blood)
• Male
• Middle Aged
• Prazosin (analogs & derivatives, therapeutic use)
• Risk Factors
• Venezuela (epidemiology)